|
The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention) Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention) conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention) Clinical research trials and The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention) healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention). The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention) Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention) clinical trial. Subjects frequently obtain the most expert healthcare possible for their The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention) condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention)  The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention)
The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention)
For Condition: Diabetes Mellitus, Non-Insulin-Dependent
Status: Recruiting
Sponsor(s): Aventis Pharmaceuticals ,
Synopsis: To determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular morbidity and/or mortality in people at high risk for vascular disease with either IFG, IGT or early type 2 diabetes; To determine whether omega-3 fatty acids can reduce cardiovascular mortality in people with IFG, IGT or early type 2 diabetes. The ORIGIN study is being conducted by the Population Health Research Institute in Hamilton, Ontario (Canada) and an independent Steering Committee. The Principal Investigators are Dr. Hertzel Gerstein and Dr. Salim Yusuf, both at Hamilton Health Sciences and the McMaster University Faculty of Health Sciences.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Factorial Assignment, Efficacy Study
Minimum Age/Maximum Age: 50 Years/
Genders: Both
Protocol Entry Criteria: Inclusion criteria: Glucose tolerance status for all candidates who are not known to have diabetes will be determined on the basis of a 75 gram oral glucose tolerance test (OGTT) that will be performed fasting (i.e. no consumption of food or beverage other than water for at least 8 hours). Two plasma glucose values will be drawn during this OGTT – a fasting value and a value drawn two hours after the 75g oral glucose load is administered (PPG). 1.Participants must have one of the following: - Impaired glucose tolerance (IGT), defined as a postprandial plasma glucose value (PPG) 140 and < 200 mg/dL ( 7.8 and < 11.1 mM), with FPG < 126 mg/dL (7.0 mM). - OR Impaired fasting glucose (IFG), defined as a fasting plasma glucose (FPG) .110 and <.126 mg/dL (.6.1 and < 7 mM), without diabetes mellitus (PPG must be < 200 mg/dL [11.1 mM]). - OR Early type 2 diabetes, defined as a FPG 126 mg/dL (7.0 mM) or a PPG of 200 mg/dL (11.1 mM) or greater, or a previous diagnosis of diabetes, and either: on no pharmacological treatment for at least 10 weeks prior to screening, with screening glycated hemoglobin < 150% of the upper limit of normal for the laboratory ( eg. < 9% if the upper limit is 6%) - OR taking one oral antidiabetic drug (OAD: from among sulfonylureas, biguanides, thiazolidinediones, alpha-glucosidase inhibitors, and meglitinides) at a stable dose for at least 10 weeks at the time of screening (or for the 10 weeks prior to hospitalization if identified while hospitalized for a CV event), with screening glycated hemoglobin < 133% of the upper limit of normal for the laboratory (eg. <.8% if the upper limit is 6%) if taking this medication at half-maximum dose or greater, and glycated hemoglobin < 142% of the upper limit of normal for the laboratory ( eg. < 8.5% if the upper limit is 6%) if taking this medication at less than half-maximum dose. 2. Men or women aged 50 years and older 3. Participants must be at risk for cardiovascular disease, based on satisfying one or more of the following criteria: - prior myocardial infarction (MI) ( 5 days prior to randomization) - prior stroke ( 5 days prior to randomization) - prior coronary, carotid or peripheral arterial revascularization - angina with documented ischemic changes (at least 2 mm ST segment depression on ECG during a Graded Exercise Test [GXT]; or with a cardiac imaging study positive for ischemia); or unstable angina with documented ischemic changes (either ST segment depression of at least 1 mm or an increase in troponin above the normal range but below the range diagnostic for acute myocardial infarction) - microalbuminuria or clinical albuminuria (an albumin: creatinine ratio > 30 mg/mg in a first morning urine sample, per ADA criteria of Jan. 2001) - left ventricular hypertrophy by electrocardiogram or echocardiogram - at least 50% stenosis on angiography of a coronary, carotid, or lower extremity artery - ankle/brachial index < 0.9. 4. Provision of signed and dated informed consent prior to any study procedures. 5. Ability and willingness to complete study diaries and questionnaires. 6. Demonstrated ability to use the self-glucose-monitoring device, and to self-inject insulin prior to randomization. 7. A negative pregnancy test for all females of childbearing potential. 8. Willingness to discontinue prior omega-3 PUFA supplements for the duration of the study. Exclusion criteria 1. Type 1 diabetes. 2. Requiring insulin treatment. 3. Known anti-GAD Ab positivity in the past. 4. Screening glycated hemoglobin 150% of the upper limit of normal for the 5.laboratory (eg. .9% if the upper limit is 6%). 5. Unwilling to inject insulin or perform self-monitoring of blood glucose 6. Nonadherence with the run-in requirement to inject placebo insulin and do capillary glucose monitoring for at least 4 days prior to randomization. 7. Coronary artery bypass grafting (CABG) within the 4 years prior to screening – however, patients with a MI or angina since a previous CABG will be eligible for randomization, even if the last CABG was within 4 years 8. Serum creatinine > 2.0 mg/dL (176 μM) at screening. 9. Active liver disease, or ALT or AST > 2.5 times upper limit of normal at screening. 10. Chronic or recurrent treatment with systemic corticosteroids, or niacin treatment for hyperlipidemia. 11. Heart failure of NYHA Functional Class III or IV. 12. Expected survival of < 3 years for non- cardiovascular causes, or cancer other than non-melanoma skin cancer within last 3 years. 13. Any other factor likely to limit protocol compliance or reporting of adverse events. 14. Unwilling or unable to discontinue thiazolidinediones. 15. Simultaneous participation in any other clinical trial of an active pharmacologic agent. 16. Unwillingness to permit sites to contact their primary physicians to communicate information about the study and the participant’s data and treatment assignment. 17. History of hypersensitivity to the investigational products. 18. Previous randomization in this study. 19. A prior heart transplant, or awaiting a heart transplant.
Total Enrollment: 10000
Location and Contact Information:
Aventis Pharmaceuticals Inc. *Recruiting*
Bridgewater, New Jersey, 08807-0800
United States
Recruiting Robert Wolf 908-304-6296
Additional Information:
Study ID Numbers: HOE 901/4032;
Study Start Date: September 2003
Record last reviewed: February 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00069784
Other Diabetes Mellitus, Non-Insulin-Dependent Studies:
1. Identification and therapy efficacy of Type 2 diabetes in Hispanic patients
2. Safety and Efficacy of INGAP-Peptide in Patients with Type 2 Diabetes
3. NNC 90-1170 Mechanism of Action: A double-blind, randomized, single-center, placebo-controlled, crossover study to examine beta-cell responsiveness to graded glucose infusion in subjects with type 2 diabetes
4. An evaluation of an oral antidiabetic agent for the treatment of type 2 diabetes
5. The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention)
Related Studies:
Other Diabetes Mellitus, Non-Insulin-Dependent Clinical Trials
Other New Jersey Clinical Trials
Other Bridgewater Clinical Trials
The ORIGIN Trial (Outcome Reduction with Initial Glargine Intervention)
|
|
|
|
|
|
|
|
